Here’s How Gilead Sciences Inc And AbbVie Inc Trumped Merck & Co Out of HCV Market

March 27, 2015 7:19 PM

14 0

Merck & Co’s two-drug therapy has been potentially booted out of the US HCV drug market already dominated by Gilead Science’s Sovaldi/Harvoni and AbbVie’s Viekira Pak

Merck & Co., Inc.(NYSE:MRK)’s combination drug of grazoprevir and elbasir for the treatment of hepatitis C virus infection, has little chance of survival in a market already dominated by major competitors including Gilead Sciences Inc (NASDAQ:GILD) and AbbVie Inc (NYSE:ABBV).

Read more

To category page